Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
Wilson Therapeutics AB (publ), announced today a poster presentation at the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, MA, 22-28 April, 2017, highlighting the results on neurological parameters from the recently completed Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease.WTX101-201 was a 24-week open-label Phase 2 study evaluating the efficacy and safety of WTX101 monotherapy in 28 newly-diagnosed adult patients with